Leukotriene receptor antagonist monotherapy ups asthma control

Leukotriene receptor antagonist monotherapy ups asthma control

(HealthDay)—As monotherapy, leukotriene-receptor antagonists (LTRAs) improve asthma control versus placebo, according to a review and meta-analysis published online Sept. 22 in the Annals of Internal Medicine.

Michael Miligkos, M.D., from the University of Thessaly School of Medicine in Larissa, Greece, and colleagues conducted a systematic review and meta-analysis to determine the benefits and harms of LTRAs as monotherapy or combined with inhaled corticosteroids compared with for adults and adolescents with asthma. Fifty trials met the eligibility criteria for inclusion.

The researchers found that LTRAs reduced the risk of an exacerbation in random-effects meta-analyses of six trials of LTRA monotherapy (summary risk ratio, 0.60; 95 percent confidence interval, 0.44 to 0.81). The summary relative risk for exacerbation was 0.80 (95 percent confidence interval, 0.60 to 1.07) in four trials of LTRAs as add-on therapy to inhaled corticosteroids. Forced expiratory volume in one second (FEV1) was increased with LTRAs as monotherapy or add-on therapy to ; the FEV1 percentage of predicted values was only improved in LTRA monotherapy . Similar adverse events rates were seen for the intervention and comparator groups.

"Leukotriene-receptor antagonists as monotherapy improved compared with placebo, but which patients are most likely to respond to treatment with LTRAs remains unclear," the authors write.


Explore further

Addition of tiotropium effective in poorly controlled asthma

More information: Full Text (subscription or payment may be required)
Journal information: Annals of Internal Medicine

Copyright © 2015 HealthDay. All rights reserved.

Citation: Leukotriene receptor antagonist monotherapy ups asthma control (2015, September 22) retrieved 21 November 2019 from https://medicalxpress.com/news/2015-09-leukotriene-receptor-antagonist-monotherapy-ups.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
10 shares

Feedback to editors

User comments